NICE recommends Darzalex to treat MM, almost two years after European approval

The U.K.'s NICE recommended this month that Janssen Biotech's Darzalex daratumumab be available through the Cancer Drugs Fund as a second-line treatment for relapsed multiple myeloma in combination with bortezomib plus dexamethasone. The European Commission granted the drug full approval for the indication in April 2017.

Darzalex, a human IgG1k mAb against CD38, is approved in several settings to treat MM, as monotherapy and in combinations...